1990-2016年全球、区域及国家结核病负担:GBD 2016研究结果
该研究基于GBD 2016,分析1990-2016年195个国家和地区的结核病负担。若趋势不变,多数国家难以实现2030年终止结核病流行目标。
核心结论
- 若当前结核病发病趋势持续,很少有国家可能实现2030年终止结核病流行的SDG目标。
- 需通过提高诊断与治疗质量及可及性、开发新工具、扩大风险因素干预、整合结核病与HIV控制规划来加速进展。
研究设计与样本
- 研究分析1990-2016年195个国家和地区的结核病负担,数据来源包括15 943 site-years生命登记数据、1710 site-years口头尸检数据、764 site-years样本生命登记数据和361 site-years死亡监测数据。
- 使用Cause of Death Ensemble模型估计结核病死亡,使用DisMod-MR 2.1(贝叶斯meta回归工具)生成发病、患病和死亡的一致性估计。
- 评估结核病负担与社会人口指数(SDI)预测负担的差异。
临床怎么用
- 临床与公共卫生应关注HIV阴性者结核病发病下降速度慢于死亡下降,需加强早期诊断和治疗可及性。
- HIV阳性者结核病发病和死亡下降较快,但仍需整合结核病与HIV控制规划。
- 耐药结核负担区域差异大,东部欧洲耐多药结核观察/预期比最高,应针对性加强防控。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although a preventable and treatable disease, tuberculosis causes more than a million deaths each year. As countries work towards achieving the Sustainable Development Goal (SDG) target to end the tuberculosis epidemic by 2030, robust assessments of the levels and trends of the burden of tuberculosis are crucial to inform policy and programme decision making. We assessed the levels and trends in the fatal and non-fatal burden of tuberculosis by drug resistance and HIV status for 195 countries and territories from 1990 to 2016. METHODS: We analysed 15 943 site-years of vital registration data, 1710 site-years of verbal autopsy data, 764 site-years of sample-based vital registration data, and 361 site-years of mortality surveillance data to estimate mortality due to tuberculosis using the Cause of Death Ensemble model. We analysed all available data sources, including annual case notifications, prevalence surveys, population-based tuberculin surveys, and estimated tuberculosis cause-specific mortality to generate internally consistent estimates of incidence, prevalence, and mortality using DisMod-MR 2.1, a Bayesian meta-regression tool. We assessed how the burden of tuberculosis differed from the burden predicted by the Socio-demographic Index (SDI), a composite indicator of income per capita, average years of schooling, and total fertility rate. FINDINGS: Globally in 2016, among HIV-negative individuals, the number of incident cases of tuberculosis was 9·02 million (95% uncertainty interval [UI] 8·05-10·16) and the number of tuberculosis deaths was 1·21 million (1·16-1·27). Among HIV-positive individuals, the number of incident cases was 1·40 million (1·01-1·89) and the number of tuberculosis deaths was 0·24 million (0·16-0·31). Globally, among HIV-negative individuals the age-standardised incidence of tuberculosis decreased annually at a slower rate (-1·3% [-1·5 to -1·2]) than mortality did (-4·5% [-5·0 to -4·1]) from 2006 to 2016. Among HIV-positive individuals during the same period, the rate of change in annualised age-standardised incidence was -4·0% (-4·5 to -3·7) and mortality was -8·9% (-9·5 to -8·4). Several regions had higher rates of age-standardised incidence and mortality than expected on the basis of their SDI levels in 2016. For drug-susceptible tuberculosis, the highest observed-to-expected ratios were in southern sub-Saharan Africa (13·7 for incidence and 14·9 for mortality), and the lowest ratios were in high-income North America (0·4 for incidence) and Oceania (0·3 for mortality). For multidrug-resistant tuberculosis, eastern Europe had the highest observed-to-expected ratios (67·3 for incidence and 73·0 for mortality), and high-income North America had the lowest ratios (0·4 for incidence and 0·5 for mortality). INTERPRETATION: If current trends in tuberculosis incidence continue, few countries are likely to meet the SDG target to end the tuberculosis epidemic by 2030. Progress needs to be accelerated by improving the quality of and access to tuberculosis diagnosis and care, by developing new tools, scaling up interventions to prevent risk factors for tuberculosis, and integrating control programmes for tuberculosis and HIV. FUNDING: Bill & Melinda Gates Foundation.
引用
- Global, regional, and national burden of tuberculosis, 1990-2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study. Lancet Infect Dis. 2018. PMID: 30507459. doi:10.1016/S1473-3099(18)30625-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。